Engineered red blood cells carrying PCSK9 inhibitors persistently lower LDL and prevent obesity

Low plasma levels of Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) are associated with decreased low-density lipoprotein (LDL) cholesterol and a reduced risk of cardiovascular disease. PCSK9 binds to the epidermal growth factor-like repeat A (EGFA) domain of LDL receptors (LDLR), very low-density...

Descripción completa

Detalles Bibliográficos
Autores principales: Deshycka, Rhogerry, Sudaryo, Valentino, Huang, Nai-Jia, Xie, Yushu, Smeding, Liyan Y., Choi, Moon Kyung, Ploegh, Hidde L., Lodish, Harvey F., Pishesha, Novalia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565730/
https://www.ncbi.nlm.nih.gov/pubmed/34731223
http://dx.doi.org/10.1371/journal.pone.0259353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565730/
https://www.ncbi.nlm.nih.gov/pubmed/34731223
http://dx.doi.org/10.1371/journal.pone.0259353

Ejemplares similares